Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Endocrinology experienced staggering growth across the board in 2025. Glucagon-like peptide-1 (GLP-1) receptor agonists have led the charge against 

, while also evolving into a key component in the management of 

 and cardiovascular complications associated with these conditions. Additionally, 

 approvals for the Biolinq Shine and Dexcom’s G7 15 Day continuous glucose monitoring system (CGM) are beginning to address the day-to-day challenges faced by many patients with both 

With so much movement in the sphere in the last 12 months, it was challenging to keep up with every bit of news coming out. The editorial team at 

 has put together a highlight reel of the 13 most impactful headlines in the endocrinology space from 2025 – catch up on some of the news you may have missed below.


FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease


On January 28, 2025, the FDA approved semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular disease death in patients with T2D and CKD. The decision was based on the phase 3b FLOW kidney outcomes trial, which highlighted semaglutide’s superior 24% relative risk reduction of all 3 endpoints compared to placebo when added to standard care.



On April 10, 2025, the FDA granted clearance to the Dexcom G7 15-day CGM system for patients with diabetes aged ≥18 years. With this approval, the G7 CGM is the longest-lasting CGM system, with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference of 8%. The device offers a waterproof sensor, direct connectivity to Apple watches, and automated activity logging, accompanied by a 12-hour grace period for transition for sensor replacement.


FDA Approves Label Expansion for Osilodrostat for Cushing's Syndrome


On April 16, 2025, parent company Recordati announced the FDA’s approval of a label extension for osilodrostat to treat endogenous hypercortisolemia in adults with Cushing’s syndrome who cannot undergo surgery or for whom it was not curative. The decision was based on the phase 3 LINC 3 study, which saw 137 patients with persistent or recurrent Cushing’s disease treated with twice-daily osilodrostat exhibit a rapid reduction in mean 24-hour urinary free cortisol concentration.


FDA Approves Lonapegsomatropin-tcgd (Skytrofa), Formerly TransCon hGH, for Adult Growth Hormone Deficiency


Lonapegsomatropin-tcgd received FDA approval on July 28, 2025, to replace endogenous growth hormone in adults with 

. This approval was based on data from foresiGHt, a phase 3 randomized clinical trial comparing weekly lonapegsomatropin-tcgd to weekly placebo and daily somatropin. After analysis, investigators saw lonapegsomatropin-tcgd showed superiority in reducing trunk fat and increasing total body lean mass at week 38 versus placebo. It was also safe and well-tolerated, with no discontinuations related to the study drug.


FDA Grants De Novo Classification to Needle-Free Glucose Monitor

On September 25, 2025, the FDA granted De Novo Classification to the Biolinq Shine, the first wearable glucose biosensor that does not require a needle for sensor placement. The device makes use of a microsensor array, which is up to 20 times more shallow than conventional glucose sensors, and aims to combine glucose, activity, and sleep information into a single device with autonomous operation. The Biolinq Shine takes the form of a patch placed on the forearm, displaying real-time glucose feedback via a primary color-coded LED display.


Oral GLP-1 Orforglipron Hits Target in Phase 3 Diabetes Trial


Results from the ACHIEVE-1 trial, published on April 17, 2025, displayed the efficacy and safety of oral orforglipron for adults with T2D inadequately controlled by diet and exercise. The once-daily GLP-1 receptor agonist lowered A1c by an average of 1.3-1.6% from a baseline of 8%, with >65% of individuals on the highest dose achieved A1c ≤6.5% - which is below the American Diabetes Association (ADA)’s threshold for diabetes. Patients also experienced an average weight loss of 16 lbs at the highest orforglipron dose, and parent company Eli Lilly noted no sign of a weight plateau by the end of the study.


CATALYST Trial: Mifepristone Improves Glycemic Control in Type 2 Diabetes with Hypercortisolism


Data from the phase 4 CATALYST trial showed the efficacy of mifepristone in improving glycemic control, reducing body weight, and decreasing waist circumference in patients with hypercortisolism and T2D. Mifepristone was associated with a least-squares mean difference in HbA1c of -1.3% compared to placebo, and secondary outcomes also suggested use was associated with weight loss and waist circumference reduction compared to placebo.


SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity


Full data from the SURMOUNT-5 was released on May 11, 2025, highlighting tirzepatide’s more substantial weight reduction compared to semaglutide in patients with overweight and obesity. The trial enrolled 751 patients, who were randomly assigned in a 1:1 ratio to the maximum tolerated dose of either tirzepatide or semaglutide. Patients treated with tirzepatide exhibited a 20.2% reduction in body weight, compared to 13.7% with semaglutide. Similarly, absolute weight loss was greater with tirzepatide, at 22.8 kg versus 15 kg. Both medications also had consistent safety profiles.


SURPASS-PEDS: Tirzepatide Achieves Superiority to Placebo in Adolescent T2D


The phase 3 SURPASS-PEDS trial was presented at the European Association for the Study of Diabetes Annual Meeting 2025, highlighting tirzepatide’s efficacy compared to placebo in patients 10-18 years with T2D inadequately controlled with metformin, basal insulin, or both. Investigators found that pooled tirzepatide doses from the trial lowered A1c by an average of 2.2% from baseline, and 86.1% of patients assigned to tirzepatide 10 mg achieved a target A1c of ≤6.5%. Tirzepatide also led to meaningful improvements in BMI, with improvements continuing through a long-term extension of 52 weeks.


ACHIEVE-3: Orforglipron Superior to Semaglutide for Type 2 Diabetes in Phase 3 Trial


On September 18, 2025, Eli Lilly announced the results from their phase 3 ACHIEVE-3 trial, which proved orforglipron’s superiority to semaglutide in T2D inadequately controlled with metformin. The trial included 4 active treatment arms, aiming to assess glycemic control and weight loss; by 52 weeks, orforglipron met the primary and all key secondary endpoints across both treatment arms. Orforglipron 12 mg lowered A1c by an average of 1.9%, while the 36 mg dose lowered it by 2.2%, compared to 1.1% and 1.4% with oral semaglutide at 7 mg and 14 mg, respectively. Orforglipron was also superior to oral semaglutide for weight loss, with orforglipron recipients losing an average of 14.6 lbs (12 mg) and 19.7 lbs (36 mg) compared to 7.9 and 11 lbs with oral semaglutide at 7 and 14 mg, respectively.


Diabetes Dialogue: 2025 Guideline Updates for Diabetes & Pregnancy


In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed the July 2025 Preexisting Diabetes in Pregnancy guidelines. Comprised of 10 key recommendations aimed at improving outcomes in pregnant individuals with type 1 or 2 diabetes, these guidelines included discontinuing GLP-1 RAs prior to conception, avoidance of metformin during pregnancy due to concerns of fetal outcomes, and the use of a hybrid closed-loop insulin delivery system rather than standard pumps.


Diabetes Dialogue: Results of ATTAIN-1 and STEP UP Phase 3 Trials


In this episode of Diabetes Dialogue, Isaacs and Bellini covered the results of the ATTAIN-1 and STEP UP clinical trials, both of which had been presented at the European Association for the Study of Diabetes 2025 Conference. They discuss the success of orforglipron, a non-peptide GLP-1 receptor agonist, in patients with obesity or overweight and without diabetes – orforglipron’s status as an oral rather than injected GLP-1 was a key focus of the discussion. Additionally, the STEP UP trial investigating semaglutide 7.2 mg in adults with obesity marks a meaningful success for a substantially higher dose than what has been approved by the FDA.


Diabetes Dialogue: Therapeutic Updates from the ADA 2026 Standards of Care


In this episode of Diabetes Dialogue, Isaacs and Bellini cover the recently released 2026 ADA Standards of Care, emphasizing therapeutic changes that may be practice-changing. GLP-1 RAs are now recommended for both 

 and CKD, and the Standards have added time-in-range goals to glucose monitoring alongside A1c targets. Additionally, Isaacs and Bellini express their excitement over the first-ever recommendation for GLP-1 RAs in patients with T1D and obesity, describing it as a major step forward, albeit a first one.

Articles

Endocrinology saw significant advancements in 2025, with GLP-1 receptor agonists playing a pivotal role in managing type 2 diabetes, obesity, chronic kidney disease, and cardiovascular complications. The FDA approved several key treatments, including semaglutide for T2D and CKD, and the Dexcom G7 CGM system. Trials like ACHIEVE-1 and SURMOUNT-5 demonstrated the efficacy of new treatments such as orforglipron and tirzepatide. Updated guidelines and therapeutic recommendations were discussed in podcasts, highlighting the evolving landscape of diabetes management and treatment strategies.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA News

Endocrinology in 2025: Year in Review

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Breaking New Ground With Oral GLP-1s in Cardiology and Weight Loss

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide an in-depth discussion of the FDA approval of oral semaglutide (oral Wegovy) for chronic weight management, with market availability anticipated as early as January 2026. The conversation centers on the clinical, regulatory, and practical implications of introducing the first oral GLP-1 receptor agonist approved specifically for weight loss, long-term weight maintenance, and cardiovascular risk reduction.

00:00:01 Intro
00:00:12 Oral Wegovy is now FDA approved
00:02:16 Cardiovascular reduction from an oral GLP-1?
00:04:55 Oral versus injectable weight loss medications
00:05:21 Specific instructions for taking oral GLP-1s
00:10:10 Uptake of oral semaglutide
00:12:12 Orforglipron versus semaglutide
00:13:37 Outro

The hosts review the evidence underpinning approval, focusing on phase 3 data from the OASIS program, including OASIS 4, which enrolled more than 300 participants, and supporting trials encompassing over 17,000 patients. Oral semaglutide, titrated up to 25 mg once daily, produced up to 14% mean weight loss at 64 weeks compared with approximately 2% with placebo – this demonstrated durable, long-term efficacy rather than short-term weight reduction. Isaacs and Bellini highlight the importance of the extended follow-up period and the consistency of weight loss outcomes, particularly given longstanding concerns about sustainability with obesity pharmacotherapy.

The discussion then shifts to the cardiovascular indication recently granted to oral semaglutide. The hosts explain that cardiovascular outcomes were not directly studied at the 25-mg oral dose in a dedicated outcomes trial. Instead, the FDA accepted extrapolation from the SELECT trial, in which injectable semaglutide 2.4 mg weekly demonstrated a 20% reduction in major adverse cardiovascular events, along with prior cardiovascular outcomes data from oral semaglutide in type 2 diabetes. Isaacs underscores the significance of this regulatory decision, noting that it avoids redundant, costly trials and accelerates patient access to therapies with well-established class effects.

The episode also addresses real-world considerations that will influence uptake. The anticipated lower cash price – reported at approximately $149 – could substantially improve access, particularly compared with injectable GLP-1–based weight loss therapies. The hosts discuss patient preferences, noting that an oral option may appeal to individuals hesitant about injections and may offer a greater sense of control despite similar pharmacokinetics and side-effect profiles.

At the same time, Isaacs and Bellini stress the critical role of patient education. Oral semaglutide requires strict administration conditions, including ingestion with limited water and no food or beverages for at least 30 minutes, as well as careful dose titration. Pills cannot be split or doubled, and improper use may significantly reduce absorption and efficacy. The episode concludes with a forward-looking discussion of payer dynamics, step-therapy considerations, and emerging oral GLP-1 agents, positioning oral semaglutide as a potentially transformative addition to obesity and cardiovascular risk management in clinical practice.

Podcasts

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits. 

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

December wrapped up 2025 with new research to curate a more granular understanding of treatment strategies in 

, especially in end-stage kidney disease (ESKD), and

. Important investigations delved into the benefits of different dialysis and transplantation modalities, while newly approved therapies and disease management strategies may guide future approaches in 

 granted Breakthrough Device Designation to Nephrodite’s Holly™ implantable, continuous dialysis system in patients with ESKD, with the proposed potential to improve the quality of life burden in patients on dialysis once first-in-human clinical trials are enabled in 2026. Furthermore, the FDA approved a supplemental New Drug Application (sNDA) for the furosemide On-Body Infusor (Furoscix) to treat edema associated with chronic heart failure (HF) and CKD in pediatric patients. Additionally, the FINE-ONE trial shed light on the promising results of finerenone in patients with IgAN, especially on key indicators of CKD severity, including reduced proteinuria and stabilized estimated glomerular filtration rate (eGFR).

Research on late-stage renal disease treatment strategies connected clinicians with informed insight into patient outcomes and specific risk factors. By understanding variations between peritoneal dialysis (PD) and hemodialysis (HD), as well as different kidney transplantation modalities, new data may support refined choices for patients and clinicians. Specifically, investigators linked increased physical activity to reduced mortality in PD and improved cognitive outcomes in PD compared to HD in respective studies. In a post-safety “safety net” era comparison between kidney-after-liver transplantation (KALT) and simultaneous liver-kidney transplantation (SLKT), investigators found notable differences in eGFR, but similar allograft survival outcomes. Overall, this research may offer a fresh perspective on renal care. 

provided editorial coverage for FDA approvals and designations, significant trials, and new disease treatment strategies to produce data-driven and patient-informed healthcare for clinicians. Read below for more key insights and data!

FDA Grants Breakthrough Device Designation to Holly Implantable Dialysis System

On December 15, 2025, the FDA granted Breakthrough Device Designation to Nephrodite’s Holly™ implantable, continuous dialysis system in patients with ESKD, supported by data from the multi-day, large animal study demonstrating sustained kidney function replacement with strong safety and performance outcomes.

“Dialysis sustains life, but at tremendous cost to a patient’s freedom and physiology,” Hiep Nguyen, MD, co-founder and SVP of Science and Technology at Nephrodite, said in a statement. “Holly represents a complete rethinking of kidney replacement, with a continuously functioning implant capable of matching the body’s natural rhythm. It’s both a scientific milestone and a human one.”

The company is preparing for Good Laboratory Practice (GLP) studies and subsequent regulatory submissions to enable first-in-human clinical trials.

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

On December 23, 2025, the FDA approved an sNDA for the furosemide On-body Infusor to treat edema associated with chronic HF and CKD in pediatric patients who weigh ≥ 43 kg. The device was previously approved in 2022 for the treatment of edema in adults with chronic HF, and in 2025, it received approval for adults with CKD. This third approval delivers all post-marketing requirements defined in the initial approval letter under the Pediatric Research Equity Act.

“The FUROSCIX ReadyFlow Autoinjector marks a key milestone in expanding patient options and improving care,” Michael Castagna, PharmD, chief executive officer at MannKind Corporation, said in a separate statement regarding the acceptance. “By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs.”

Finerenone Shows Promise in IgAN: Reduced Proteinuria, Stable Kidney Function

In patients with IgAN receiving full supportive care, treatment with finerenone has demonstrated a significant reduction in their protein-to-creatinine ratio in addition to a stabilized eGFR.

In the FINE-ONE trial, investigators observed a 28.48% (

 = .003) reduction in proteinuria at 2 and 6 months, respectively, compared with baseline. At 8 months, proteinuria decreased 39.69%, falling from 0.38 (0.28 to 0.75) g/g to 0.24 (0.16 to 0.47) g/g (

 = .02). Investigators further noted statistically insignificant eGFR fluctuations at 2 and 4 months, 54.99 ± 27.49 mL/min/1.73 m² (

 = .42) and 58.77 ± 15.78 mL/min/1.73 m² (

Safety Net’s Kidney After Liver Transplant Linked to Reduced eGFR

When comparing outcomes between the ESKD treatment modalities, KALT and SLKT, in accordance with the Organ Procurement and Transplantation Network’s 2017-established safety net era, research demonstrated similar allograft survival, but different eGFR.

At 1-year post-kidney transplant, investigators noted similar kidney allograft survival rates, with 97.7% for KALT (95% Confidence Interval [CI], 96.0 to 98.7) and 96.8% for SLKT (95% CI, 96.0 to 97.4; 

 = .43). Patient survival rates were increased in KALT with a rate of 96.7% (95% CI, 94.8 to 98.0) compared to 93.9% in SLKT (95% CI, 92.9 to 94.8; P = .02). The mean difference in eGFR between KALT and SLKT was −4.7 mL/min/1.73 m2 (95% CI, −7.0 to −2.4; 

 <.001) in the propensity score matched analysis.

Podometrics Could Guide IgAN Treatment While Reducing Invasiveness

Based on the podocyte depletion hypothesis, investigators conducted a retrospective, single-center observational cohort study to evaluate podometric's ability to monitor disease activity. Analyzing kidney biopsy specimens from patients with IgAN, investigators measured the associations between podometric parameters, Oxford classification, and eGFR.

Multivariate analysis revealed reduced podocyte number as the only factor independently associated with eGFR decline. Patients with established markers of chronic kidney damage, such as segmental sclerosis (S1) and tubular atrophy/interstitial fibrosis (T1/2), had decreased podocyte density and number. Additionally, investigators found an association between elevated podocyte markers, NPHS1 and NPHS2, with E1 and C1/C2 lesions.

Peritoneal Dialysis Linked To Improved Cognitive Function In CKD

Research compared PD to HD in patients with CKD, reporting improved cognitive outcomes associated with PD. Regardless of findings, investigators emphasized the importance of individualized dialysis modalities.

The pooled analysis demonstrated benefits from PD by the majority of factors assessed, including executive function (Standardized Mean Difference [SMD], − 0.39; 95% CI, − 0.61 to − 0.16; 

], 31%), global cognitive function (SMD, − 0.46; 95% CI, − 0.62 to − 0.29; 

, 49%), reduced risk of dementia (Odds Ratio [OR], 1.68; 95% CI, 1.25 to 2.25; 

, 94%), increased processing speed (SMD, − 0.28; 95% CI − 0.47 to − 0.08; 

, 0%), and memory scores (SMD, − 0.35; 95% CI, − 0.62 to − 0.06; 

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

December 2025 saw significant advancements in chronic kidney disease (CKD) treatment, particularly in end-stage kidney disease (ESKD) and IgA nephropathy (IgAN). Key developments included the FDA's Breakthrough Device Designation for Nephrodite’s Holly™ implantable dialysis system and approval of the furosemide On-Body Infusor for pediatric patients. The FINE-ONE trial highlighted finerenone's efficacy in reducing proteinuria and stabilizing eGFR in IgAN patients. Research also compared peritoneal dialysis (PD) and hemodialysis (HD), revealing improved cognitive outcomes with PD and differences in eGFR between kidney-after-liver and simultaneous liver-kidney transplantation.

In December 2025, intervention strategies, dialysis modalities, and kidney transplantation data provided insight to improve renal care for clinicians. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

6 Nephrology Headlines You Missed in December 2025

Sophia Thomas, DNP, APRN, FNP-BC, PPCNP-BC, FAANP, FNAP, FAAN, former president of the American Association of Nurse Practitioners and nurse practitioner at DePaul Community Health Centers

Sophia Thomas, DNP, APRN, FNP-BC, PPCNP-BC, FAANP, FNAP, FAAN

Clinical services have historically embraced nurse practitioners (NPs) to deliver 

 care, including diagnosing allergy and interpreting blood test results. NPs play a vital role in diagnosing and managing allergies in patients with asthma. Among 7.7% of Americans with 

, about two-thirds have a clinical allergy.

Most patients with asthma are managed by primary care clinicians, with only 22% regularly treated by a specialist.

 According to the Centers for Disease Control and Prevention (CDC), about 40% of primary care visits are for 

 With clinician shortages and longer wait times for both primary care providers and allergists, specific IgE (sIgE) blood testing offers a cost-effective, efficient option for care teams, including NPs, to get to the root causes of their patients’ symptoms. Blood tests can help improve allergy and asthma management, reduce the risk for related complications, save clinicians’ time by preventing unscheduled appointments, and improve patient safety and outcomes in the long term.

Why allergy histories matter in clinical care

There are a few important factors to keep in mind when establishing a patient’s history during a primary care visit. It can be easy for patients to confuse allergies, sensitivities, and side effects, which can lead to inaccurate chart notes.

Symptom records could be documented without clarification. For example, an adult patient may reference a reaction they once had as a child but their records may not state the age they had the reaction. Incomplete or inaccurate patient histories can create long-term chart errors and undermine clinical decision-making.

This is why capturing a patient’s clinical history is the most important step of the diagnostic process. A thorough patient history should assess symptoms consistent with IgE-mediated allergy. These reactions, typically occurring within minutes to a few hours after allergen exposure, can affect the skin, gastrointestinal tract, cardiovascular system, and/or respiratory tract. An exception is certain delayed responses, such as those seen in alpha-gal syndrome, a mammalian meat allergy.

Clinicians should document when symptoms occur, their frequency, potential triggers, the location of where they occurred (i.e. work or home), and eating habits to help identify possible food and environmental allergens. Reactions should also be consistently reproducible under similar conditions to support an accurate diagnosis.

Many patients never receive confirmatory testing of their allergies, with most allergy histories relying on self-reported data. Up to 35% of people self-diagnose food allergy or intolerance to foods and self-manage the condition, rather than seek a clinical diagnosis.

 Individuals who self-diagnose may adopt restrictive diets that can cause avoidable nutritional gaps, spending money on ineffective supplements, or taking antihistamines unnecessarily, all while the root cause of their symptoms remains unaddressed.

Moreover, researchers have long known that the frequency of children with allergies who also have asthma can be as high as 90%.

Recent research has shown that about 75% of adults aged 20 to 40 years with asthma, and 65% of those with asthma aged ≥ 55 years have ≥ 1 allergic trigger.

 For allergy patients who are wheezing or coughing, care teams can help them devise a treatment plan to manage both their respiratory allergies and asthma.

In vitro blood tests, including ImmunoCAP™specific IgE methods, are essential for identifying patients’ allergic triggers.

 These tests, comparable to skin prick testing, measures the amount of specific IgE antibodies that develop as an immune response to allergens and are easily accessible to both specialty and primary care clinicians. This specific IgE testing is commonly offered for common indoor allergens alongside region-specific respiratory allergens (i.e. local grass, tree, and weed pollen) to to help determine the environmental factors that affect patients living in their geographical area.

Serological testing for specific IgE is convenient for patients and only requires a relatively small amount of sera to assess a comprehensive profile of suspected allergens. This test can also help determine if a patient is atopic, meaning that they have a genetic predisposition to develop allergic conditions like asthma, allergic rhinitis, and atopic dermatitis.

 Unlike skin prick testing, there is no need for patients to stop any medications before testing. The availability of these clinical laboratory profiles across national and regional locations makes allergy testing an affordable tool that NPs can integrate into their routine asthma and allergy management.

The role of patient education in allergy management

Identifying allergic triggers through specific IgE testing enables the development of customized treatment plans that combine exposure reduction strategies with appropriate medications. NPs play a critical role by helping to provide tailored education on how to avoid food and environmental allergen exposure and to wok along alongside the patient’s broader care team to empower them to understand and manage their symptoms. Educating the patient can help reduce anxiety, improve medication adherence, and create safer home and school environments, leading to improved long-term health outcomes.

ACAAI. Facts and Stats - 8.3% of Americans Have Asthma. ACAAI Patient. Published 2023. 

https://acaai.org/asthma/asthma-101/facts-stats/

.What does asthma have to do with your allergies? Probably a lot. ACAAI Public Website. Published July 14, 2023. 

https://acaai.org/resource/what-does-asthma-have-to-do-with-your-allergies-probably-a-lot/

Stepanović A, Kopač P, Rotar Pavlič D. Family Physicians’ Awareness of the Burden of Oral Corticosteroids in Asthma Patients. 

 doi:https://doi.org/10.5644/ama2006-124.446

Ashman J, Santo L, Okeyode T. Characteristics of Office-based Physician Visits by Age, 2019. 

National Health Statistics Reports Number

https://www.cdc.gov/nchs/data/nhsr/nhsr184.pdf

Why Do People Misdiagnose Themselves with Food Hypersensitivity? An Exploration of the Role of Biopsychosocial Factors

https://www.emjreviews.com/wp-content/uploads/2019/03/Why-Do-People-Misdiagnose-Themselves-with....pdf

 Allergy Testing Solutions. Thermo Fisher Scientific. Published 2017. 

https://www.thermofisher.com/phadia/us/en/our-solutions/immunocap-allergy-solutions.html

Atopy: Disease, Causes, Triggers, Conditions & Treatment. Cleveland Clinic. Published October 3, 2024. 

https://my.clevelandclinic.org/health/diseases/atopy

Nurse practitioners (NPs) are integral in allergy care, especially for asthma patients, where two-thirds have clinical allergies. With clinician shortages, specific IgE blood testing offers a cost-effective solution for identifying allergy triggers, improving management, and reducing complications. Accurate patient histories are crucial for effective diagnosis, as self-reported data often leads to misdiagnosis and unnecessary dietary restrictions. In vitro blood tests, like ImmunoCAP™, are essential for identifying allergic triggers and are accessible to both primary and specialty care clinicians. Patient education by NPs enhances management, reducing anxiety and improving outcomes.

Nurse practitioners play a key role in allergy and asthma care using specific IgE blood testing to identify triggers, improve outcomes, and ease shortages.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Seasonal Allergy

Understanding Allergies from Bedside to Blood Test

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Summary of the phase 3b APEX study showing guselkumab’s efficacy and inhibition of structural joint damage.

Expert Perspectives on Rheumatologic Referral for Psoriatic Arthritis

, despite the expanding therapeutic landscape. Linda Stein Gold, MD, and her colleagues analyze patient- and provider-reported data from the 

 surveys, revealing that many patients remain dissatisfied with current therapies and that oral agents are overwhelmingly preferred over injectables. The experts discuss how patient lifestyle, comorbidities, and psychosocial burden influence shared decision-making and treatment adherence. They also interpret the 

International Psoriasis Council’s (IPC)

 and explore its implications for reducing “topical churn” and advancing systemic therapy earlier in the disease course.

 and its potential to close current gaps in care. The panel provides an in-depth review of the 

 clinical development program, summarizing the 

 trials, which demonstrated superior efficacy versus deucravacitinib at both 16 and 24 weeks, with favorable safety and tolerability. They also discuss new 

 showing sustained clearance and no new safety signals in adults and adolescents. The faculty reflect on ICO’s implications for adolescent psoriasis and how early, aggressive oral intervention may help prevent progression to psoriatic arthritis, marking a significant milestone in the evolution of oral IL-23–targeted therapy.

The final portion of the series shifts focus to 

managing active psoriatic arthritis (PsA)

. The experts discuss new findings from the 

 demonstrated the first clear evidence of IL-23–mediated inhibition of structural joint damage, reinforcing the rationale for early biologic use in high-risk patients. They compare APEX to prior IL-23 studies, discuss implications for therapy sequencing, and highlight other emerging data from 

 studies. In closing, Stein Gold and colleagues emphasize a forward-looking approach that integrates personalized therapy selection, early detection of PsA, and cross-specialty collaboration to elevate standards of psoriasis care

Videos

Video Series

The panel discusses the prevalence and risk factors for psoriasis progression to psoriatic arthritis.

Screening for Psoriatic Arthritis in Patients With Psoriasis 

Shyam Joshi explores the expected incorporation of new therapies within updated CSU guidelines and their anticipated impact on clinical management strategies.


Anticipated Role of New Therapies in CSU Guidelines, Management

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The 2025 cholangitis year in review covers PBC and PSC advances, FDA designations, trial data, and evolving treatment pathways.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Cholangitis in 2025: Year in Review

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

This episode spotlights how advancements in 2025, including data from AASLD 2025, set the stage for future standards of care in cholestatic liver disease. 

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

This Year In Medicine

Liver Lineup: Breakthroughs in Cholestatic Liver Disease in 2025

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

PROMIS Outcome Measures Effective for Evaluating Chronic Skin Disease

The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

Latest News

Endocrinology in 2025: Year in Review

Diabetes Dialogue: Breaking New Ground With Oral GLP-1s in Cardiology and Weight Loss

6 Nephrology Headlines You Missed in December 2025

Understanding Allergies from Bedside to Blood Test

Expert Perspectives on Rheumatologic Referral for Psoriatic Arthritis